Seeking Alpha

Acorda Therapeutics Inc. (ACOR)

()

News & PR
Market Currents

Buzz
Twitter: ACOR

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Tuesday Options Update: SKX, FXI, SBUX, VIX & ACOR

Dec 22 • Andrew Wilkinson • Comment!
On Small Cap Drug Makers and Volatility

Oct 18 • Justin M. Hall • 6 Comments
Equities Update: Late Rally

Oct 15 • Midnight Trader • 4 Comments
Positive FDA Panel Outcome for Acorda Therapeutics

Oct 15 • Mike Havrilla • 1 Comment
Tuesday Options Recap

Oct 13 • Frederic Ruffy • 1 Comment
A Mixed Bag for Traders and Investors in Healthcare

Oct 12 • M. E. Garza • Comment!
Stage Set for Acorda Bounce?

Oct 11 • M. E. Garza • 1 Comment
Equities: Rally Revives as DJIA Hits Year's Highs

Oct 9 • Midnight Trader • 5 Comments
Friday Options Recap

Oct 9 • Frederic Ruffy • 5 Comments
FDA Calendar Updates: Acorda, Amgen

Aug 4 • Mike Havrilla • Comment!
Dealmaking Sweeps the Biotech Sector

Jul 5 • The Burrill Report • Comment!
FDA Calendar Updates: Repros, Discovery, Acorda, Human Genome Sciences

Jul 2 • Mike Havrilla • 3 Comments
Preview from Europe: Stocks Jump Out of the Gate Before Fading

Jul 2 • The Mole • Comment!
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch

Jun 28 • Marco Hickey • 1 Comment
Bullish on Acorda: New Drug Looks Promising

Jun 23 • Zacks.com • Comment!
Monday Options Update: KMB, S, EEM, XLU, UAUA & ACOR

Jun 15 • Andrew Wilkinson • Comment!
Q1 2009 Biotech Earnings Roundup: The Good, the Bad, and the Ugly

May 27 • Mark Cifra • 4 Comments
Acorda Pops on Good News

May 7 • Zacks.com • Comment!
FDA Calendar Updates: Acorda, Roche

May 7 • Mike Havrilla • Comment!
Why I Doubt the FDA Will Approve Acorda's Fampridine

Apr 24 • Dr. Anthony • 12 Comments
Thursday's Pre-Market Report:

Apr 23 • Midnight Trader • Comment!
FDA, Clinical Trial Calendar Updates: Acorda, Alkermes, GTx

Apr 23 • Mike Havrilla • Comment!
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly

Apr 2 • Mark Cifra • 5 Comments
FDA and Clinical Trial Updates: Weight Loss, Diabetes and More

Apr 2 • Mike Havrilla • 3 Comments
Tuesday's Options Recap

Mar 31 • Frederic Ruffy • 4 Comments
Acorda Down on FDA Delay

Mar 31 • Zacks.com • Comment!
Where Might Genentech Investors Redeploy $47B?

Mar 16 • Michael Becker • 2 Comments
Behind the Acorda Rumors

Feb 26 • Bill Luby • Comment!
Wall Street Breakfast: Must-Know News

Feb 25 • SA Editor Rachael Granby • 14 Comments
FDA Decisions and Clinical Trials: An Updated Calendar

Feb 6 • Mike Havrilla • 2 Comments
Monday Options Update: EWJ, XLF, ACOR, TWC & GE

Feb 2 • Andrew Wilkinson • 1 Comment
SAC Capital Portfolio Update: 37 13G Filings

Jan 15 • Market Folly • Comment!
20 Emerging Healthcare Stocks to Watch in '09

Jan 11 • Mike Havrilla • 4 Comments
9 Possible Pharma Deals for 2009

Jan 8 • Zacks.com • 7 Comments
A Biotech Bloom in July

Jul 28, 2008 • Option Dragon • 10 Comments
MS Drug Fampridine Sends Acorda Stock Way Up

Jun 3, 2008 • Eben Tessari • 9 Comments
Icahn's Hedge Fund Has New Stakes In Genzyme and Childrens Place, Among Others

Nov 15, 2007 • Lon Juricic • Comment!
Acorda Therapeutics: Sell or Short?

Oct 1, 2007 • Martin Roth • Comment!
Loeb's Third Point Issues Latest 13F: Summary of Holdings

Aug 16, 2007 • Lon Juricic • Comment!
Loeb's Third Point LLC Lowering Its Stake in Acorda

May 25, 2007 • Lon Juricic • Comment!
Biotech Week in Review: Holding Steady

Feb 26, 2007 • Centient Biotech Investor • Comment!

Acorda Therapeutics Inc. (ACOR)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers